Xenon Pharmaceuticals price target raised, coverage transferred at Stifel. Stifel analyst Paul Matteis took over coverage of Xenon Pharmaceuticals from Stephen Willey with a maintained Buy rating and raised price target of $21, up from the prior target of $18. Matteis believes just one of Xenon’s three lead epilepsy assets needs to succeed to drive the stock meaningfully higher from current levels, he tells investors.
https://thefly.com/landingPageNews.php?id=2886049
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.